Leap Therapeutics Inc (NASDAQ:LPTX) — Market Cap & Net Worth
Market Cap & Net Worth: Leap Therapeutics Inc (LPTX)
Leap Therapeutics Inc (NASDAQ:LPTX) has a market capitalization of $116.14 Million ($116.14 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #18717 globally and #4344 in its home market, demonstrating a 391.14% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Leap Therapeutics Inc's stock price $2.05 by its total outstanding shares 56651840 (56.65 Million). Also see how large is Leap Therapeutics Inc's balance sheet for a full breakdown of the balance sheet.
Leap Therapeutics Inc Market Cap History: 2017 to 2025
Leap Therapeutics Inc's market capitalization history from 2017 to 2025. Data shows change from $3.54 Billion to $116.14 Million (-33.92% CAGR). Also see Leap Therapeutics Inc operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Index Memberships
Leap Therapeutics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.67 Trillion | 0.00% | #527 of 976 |
|
NASDAQ Composite
IXIC
|
$41.95 Trillion | 0.00% | #1812 of 3165 |
Weight: Leap Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Leap Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Leap Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check LPTX share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
679.82x
Leap Therapeutics Inc's market cap is 679.82 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $634.50 Million | $375.00K | -$32.90 Million | 1692.00x | N/A |
| 2020 | $1.27 Billion | $10.05 Million | -$3.39 Million | 126.79x | N/A |
| 2021 | $1.84 Billion | $1.50 Million | -$40.59 Million | 1223.68x | N/A |
| 2022 | $254.93 Million | $375.00K | -$54.60 Million | 679.82x | N/A |
Competitor Companies of LPTX by Market Capitalization
Companies near Leap Therapeutics Inc in the global market cap rankings as of September 18, 2026. Review LPTX goodwill-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Leap Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
Leap Therapeutics Inc Historical Marketcap From 2017 to 2025
Between 2017 and today, Leap Therapeutics Inc's market cap moved from $3.54 Billion to $ 116.14 Million, with a yearly change of -33.92%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $116.14 Million | -28.70% |
| 2024 | $162.87 Million | -30.64% |
| 2023 | $234.82 Million | -7.89% |
| 2022 | $254.93 Million | -86.11% |
| 2021 | $1.84 Billion | +44.00% |
| 2020 | $1.27 Billion | +100.89% |
| 2019 | $634.50 Million | -44.00% |
| 2018 | $1.13 Billion | -67.95% |
| 2017 | $3.54 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Leap Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $116.14 Million USD |
| MoneyControl | $116.14 Million USD |
| MarketWatch | $116.14 Million USD |
| marketcap.company | $116.14 Million USD |
| Reuters | $116.14 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Leap Therapeutics Inc
Cypherpunk Technologies Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead clinical stage drug candidate includes DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in various ongoing clinical trials for treating esophagogastric and gynecologic cancers, and colorectal cancer. The company also develops FL-… Read more